Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 5;11(10):2375.
doi: 10.3390/nu11102375.

The Gut Microbiota in Celiac Disease and probiotics

Richa Chibbar  1 , Levinus A Dieleman  2
Affiliations
Review

The Gut Microbiota in Celiac Disease and probiotics

Richa Chibbar et al. Nutrients. .

Abstract

Celiac disease (CeD) is an immune-mediated enteropathy, and unique in that the specific trigger is known: gluten. The current mainstay of therapy is a gluten-free diet (GFD). As novel therapies are being developed, complementary strategies are also being studied, such as modulation of the gut microbiome. The gut microbiota is involved in the initiation and perpetuation of intestinal inflammation in several chronic diseases. Intestinal dysbiosis has been reported in CeD patients, untreated or treated with GFD, compared to healthy subjects. Several studies have identified differential bacterial populations associated with CeD patients and healthy subjects. However, it is still not clear if intestinal dysbiosis is the cause or effect of CeD. Probiotics have also been considered as a strategy to modulate the gut microbiome to an anti-inflammatory state. However, there is a paucity of data to support their use in treating CeD. Further studies are needed with therapeutic microbial formulations combined with human trials on the use of probiotics to treat CeD by restoring the gut microbiome to an anti-inflammatory state.

Keywords: Celiac disease; gut microbiota; probiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

References

    1. Ludvigsson J.F., Leffler D.A., Bai J.C., Biagi F., Fasano A., Green P.H., Hadjivassiliou M., Kaukinen K., Kelly C.P., Leonard J.N., et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62:43–52. doi: 10.1136/gutjnl-2011-301346. - DOI - PMC - PubMed
    1. Fasano A., Catassi C. Celiac Disease. N. Engl. J. Med. 2012;367:2419–2426. doi: 10.1056/NEJMcp1113994. - DOI - PubMed
    1. Kelly C.P., Bai J.C., Liu E., Leffler D.A. Celiac disease: Clinical spectrum and management. Gastroenterology. 2015;148:1175–1186. doi: 10.1053/j.gastro.2015.01.044. - DOI - PMC - PubMed
    1. Caio G., Volta U., Sapone A., Leffler D.A., De Giorgio R., Catassi C., Fasano A. Celiac Disease: A comprehensive current review. BMC Med. 2019;17:142. doi: 10.1186/s12916-019-1380-z. - DOI - PMC - PubMed
    1. Singh P., Arora A., Strand T.A., Leffler D.A., Mäki M., Kelly C.P., Ahuja V., Makharia G.K. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2018;16:823–836. doi: 10.1016/j.cgh.2017.06.037. - DOI - PubMed